학술논문
Clinical relevance of thymic and bone marrow outputs in multiple sclerosis patients treated with alemtuzumab.
Document Type
Academic Journal
Author
Sottini A; Diagnostic Laboratory, Diagnostic Department, ASST Spedali Civili di Brescia, Brescia, Italy. Electronic address: alessandra.sottini@asst-spedalicivili.it.; Quaresima V; Diagnostic Laboratory, Diagnostic Department, ASST Spedali Civili di Brescia, Brescia, Italy.; Barbaro M; Diagnostic Laboratory, Diagnostic Department, ASST Spedali Civili di Brescia, Brescia, Italy; Laboratorio analisi, Ospedale Civile di Sondrio, ASST Valtellina e Alto Lario, Sondrio, Italy.; Moiola L; Neurology Department-Multiple Sclerosis Center, IRCCS San Raffaele Institute, Vita-Salute San Raffaele University, Milan, Italy.; Filippi M; Neurology and Neurorehabilitation Units, MS Center, Headache Center, Epilepsy Center, and Stroke Unit, Neurophysiology Service, and Neuroimaging Research Unit, Division of Neuroscience, San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy.; Malentacchi M; SCDO Neurologia e Centro di Riferimento Regionale Sclerosi Multipla, AOU San Luigi Gonzaga, Orbassano, Italy.; Capobianco M; SCDO Neurologia e Centro di Riferimento Regionale Sclerosi Multipla, AOU San Luigi Gonzaga, Orbassano, Italy.; Puthenparampil M; Department of Neuroscience (DNS), School of Medicine - University of Padua, Padua, Italy.; Gallo P; Department of Neuroscience (DNS), School of Medicine - University of Padua, Padua, Italy.; Cocco E; Centro Sclerosi Multipla AOU Cagliari - University of Cagliari, Italy.; Frau J; Centro Sclerosi Multipla ASL Cagliari, Italy.; Zaffaroni M; Centro Sclerosi Multipla, Ospedale di Gallarate, ASST della Valle Olona, Gallarate, Italy.; Guaschino C; Centro Sclerosi Multipla, Ospedale di Gallarate, ASST della Valle Olona, Gallarate, Italy.; Stampatori C; Centro Regionale per la Sclerosi Multipla, ASST Spedali Civili di Brescia, Montichiari, Brescia, Italy.; Mancinelli C; Centro Regionale per la Sclerosi Multipla, ASST Spedali Civili di Brescia, Montichiari, Brescia, Italy; U.O. Neuroimmunologia e Malattie Neuromuscolari, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.; Brambilla L; U.O. Neuroimmunologia e Malattie Neuromuscolari, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.; Clerici VT; U.O. Neuroimmunologia e Malattie Neuromuscolari, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.; Vianello M; UO Neurologia, ULSS 2 Marca Trevigiana, Treviso, Italy.; Vitetta F; Centro Malattie Demielinizzanti, Ospedale Civile Baggiovara, AOU Modena, Italy.; Ferraro D; Centro Malattie Demielinizzanti, Ospedale Civile Baggiovara, AOU Modena, Italy.; Rosettani P; Clinica Neurologica, Azienda Ospedaliero Universitaria delle Marche, Torrette, Ancona, Italy.; Danni MC; Clinica Neurologica, Azienda Ospedaliero Universitaria delle Marche, Torrette, Ancona, Italy.; Conti M; Department of Neurology, Papa Giovanni XXIII Hospital, Bergamo, Italy.; Grimoldi M; Department of Neurology, Papa Giovanni XXIII Hospital, Bergamo, Italy.; Capra R; Centro Regionale per la Sclerosi Multipla, ASST Spedali Civili di Brescia, Montichiari, Brescia, Italy.; Imberti L; Diagnostic Laboratory, Diagnostic Department, ASST Spedali Civili di Brescia, Brescia, Italy; Section of Microbiology, University of Brescia, P. le Spedali Civili, 1, Brescia, Italy.
Source
Publisher: Elsevier/North-Holland Country of Publication: Netherlands NLM ID: 8109498 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1872-8421 (Electronic) Linking ISSN: 01655728 NLM ISO Abbreviation: J Neuroimmunol Subsets: MEDLINE
Subject
Language
English
Abstract
Thymic and bone marrow outputs were evaluated in 13 sequential samples of 68 multiple sclerosis patients who initiated alemtuzumab and were clinically followed for 48 months. Three months after alemtuzumab infusions, the levels of new T lymphocytes were significantly reduced, but progressively increased reaching the highest values at 36 months, indicating the remarkable capacity of thymic function recovery. Newly produced B cells exceeded baseline levels as early as 3 months after alemtuzumab initiation. Heterogeneous patterns of new T- and B-cell recovery were identified, but without associations with age, sex, previous therapies, development of secondary autoimmunity or infections, and disease re-emergence. Trial registration version 2.0-27/01/2016.
Competing Interests: Declaration of Competing Interest The authors declare no conflicts of interest with the manuscript. The funding source had no influence on the study design, collection, analysis, and data interpretation. The funding source was not involved in the decision to publish.
(Copyright © 2023 The Authors. Published by Elsevier B.V. All rights reserved.)
Competing Interests: Declaration of Competing Interest The authors declare no conflicts of interest with the manuscript. The funding source had no influence on the study design, collection, analysis, and data interpretation. The funding source was not involved in the decision to publish.
(Copyright © 2023 The Authors. Published by Elsevier B.V. All rights reserved.)